The antidepressant clomipramine induces programmed cell death in Leishmania amazonensis through a mitochondrial pathway.

Parasitol Res

Programa de Pós-Graduação em Ciências Biológicas, Área de Concentração Biologia Celular e Molecular, Universidade Estadual de Maringá, Maringá, Paraná, Brazil.

Published: March 2019

Despite many efforts, the currently available treatments for leishmaniasis are not fully effective. To discover new medications, drug repurposing arises as a promising strategy. We present data that supports the use of the antidepressant clomipramine against Leishmania amazonensis. The drug presented selective activity at micromolar range against both the parasite forms and stimulated nitric oxide production in host macrophages. Regarding the mechanism of action, clomipramine led parasites do mitochondrial depolarization, which coupled with the inhibition of trypanothione reductase induced strong oxidative stress in the parasites. The effects observed in promastigotes included lipoperoxidation, plasma membrane permeabilization, and apoptosis hallmarks (i.e., DNA fragmentation, phosphatidylserine exposure, and cell shrinkage). The mechanism of action in both parasitic forms was quite similar, but amastigotes also exhibited energetic stress, reflected by a reduction of adenosine triphosphate levels. Such differential effects might be attributable to the metabolic particularities of each form of the parasitic. Ultrastructural alterations of the endomembrane system and autophagy were also observed, possibly indicating an adaptive response to oxidative stress. Our results suggest that clomipramine interferes with the redox metabolism of L. amazonensis. In spite of the cellular responses to recover the cellular homeostasis, parasites underwent programmed cell death.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00436-018-06200-xDOI Listing

Publication Analysis

Top Keywords

antidepressant clomipramine
8
programmed cell
8
cell death
8
leishmania amazonensis
8
mechanism action
8
oxidative stress
8
clomipramine induces
4
induces programmed
4
death leishmania
4
amazonensis mitochondrial
4

Similar Publications

Adequacy of treatment in outpatients with obsessive-compulsive disorder.

Compr Psychiatry

January 2025

Department of Psychiatry, Amsterdam UMC, Amsterdam, The Netherlands; Amsterdam Neuroscience Research Institute, Amsterdam, The Netherlands; Arkin Institute for Mental Health, Amsterdam, The Netherlands.

Objective: To examine whether patients with obsessive-compulsive disorder (OCD) are adequately treated with pharmacotherapy before referral to a specialized center for OCD.

Methods: We performed a retrospective chart review of patients with OCD who were seen for intake at an academic outpatient center in The Netherlands between 2016 and 2023. We collected data on age, gender, illness severity using the Yale-Brown Obsessive-Compulsive Scale, duration of illness, comorbidity and past pharmacotherapy and psychotherapy.

View Article and Find Full Text PDF
Article Synopsis
  • Empagliflozin, an SGLT2 inhibitor, was tested for its antidepressant effects in diabetic rats using a model that simulates neuroinflammation-mediated depression after performing olfactory bulbectomy (OBX) surgery.
  • The study involved treating the rats with oral doses of empagliflozin, metformin, and clomipramine over 14 days, and measuring changes in behavior and antioxidant levels.
  • Results indicated that empagliflozin improved depressive behaviors and restored antioxidant levels in the brain, suggesting it may help treat depression linked to neuroinflammation and oxidative stress.
View Article and Find Full Text PDF
Article Synopsis
  • Previous randomized controlled trials have largely shown that antidepressants do not provide significant benefits for restricted and repetitive behaviors (RRBs) in individuals with autism spectrum disorder (ASD).
  • A systematic review of nine trials involving 609 participants found no notable differences in RRB outcomes between those treated with antidepressants and those given a placebo.
  • Only specific antidepressants like clomipramine and fluvoxamine showed some positive effects in small preliminary studies, but these findings need to be verified in larger trials.
View Article and Find Full Text PDF

Introduction: Antidepressants may lead to a series of sexual adverse effects (SAEs), among which ejaculation dysfunction (EjD) is often overlooked by clinicians. The purpose of the present network meta-analysis was to assist drug adjustment by comparing and ranking the incidence of EjD among various antidepressants.

Methods: Relevant studies were retrieved from PubMed, Embase, Scopus, Web of Science, ClinicalTrials.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!